Overview

• RES-010 is an antisense oligonucleotide that blocks miR-22 to reprogram lipid handling, mitochondrial activity and adipose remodeling rather than suppress appetite.
• In non-human primates, RES-010 cut fat mass by 15% with about 1% lean mass loss over 10 weeks, compared with semaglutide’s 16% fat and 8% lean loss.
• Obese mice given weekly injections lost roughly 12% more weight than controls over five months despite similar food intake, and they did not regain weight after treatment stopped.
• After semaglutide discontinuation, primates on the combination avoided weight regain when continued on RES-010 alone, and no rebound occurred after RES-010 cessation a few weeks later.
• Developers reported no significant adverse effects at therapeutic doses in animals, and independent experts called for peer-reviewed data and human trial outcomes before drawing conclusions.